Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole.

doi:10.1080/13693780400029528

Paper

Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole.

Published Sep 1, 2005 · Y. Morera-López, J. M. Torres-Rodríguez, Teresa Jiménez-Cabello

Medical mycology

Q1 SJR score

37

Citations

1

Influential Citations

Full textSemantic Scholar

Abstract

Minimal inhibitory concentrations (MIC) and minimal fungicidal activity of albaconazole, voriconazole and fluconazole against 55 strains of Cryptococcus gattii, clinically or environmentally isolated in Spain and some Latin American countries, were assessed. By means of the microbroth method (National Committee for Clinical Laboratory Standards; document M27-A2), the geometric mean value for fluconazole was 5.01 microg/ml; however, MIC for 12.7% of isolates ranged from 16 to 32 microg/ml, suggesting increased resistance against fluconazole. Geometric mean values of 0.02 and 0.03 microg/ml for albaconazole and voriconazole, respectively, were found, indicating not only a higher susceptibility to these new azoles but also a better performance of albaconazole (P = 0.003). Minimal fungicidal concentrations were also very low for albaconazole and voriconazole (P<0.001; geometric mean values of 0.023 microg/ml and 0.07 microg/ml, respectively). Both azoles may be good alternatives for the treatment of C. gattii cryptococcosis.

In Vitro Study

Study Snapshot

Albaconazole and voriconazole show higher susceptibility and better performance against Cryptococcus gattii, making them potential alternatives for treating C. gattii cryptococcosis.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

Cryptococcus gattii: in vitro susceptibility to the new antifungal albaconazole versus fluconazole and voriconazole.

References

Epidemiology of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre- and post-HAART eras

Post-HAART era in France saw a 46% decrease in HIV-associated cryptococcosis cases, with demographic factors like African origin, older age, and heterosexual HIV contamination increasing the risk.

In Vitro and In Vivo Efficacies of the New Triazole Albaconazole against Cryptococcus neoformans

Albaconazole is 100-fold more potent than fluconazole in vitro and as effective as fluconazole for treating cryptococcal meningitis in rabbits.

Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.

Voriconazole concentrations in cerebrospinal fluid and brain tissue vary between immunocompetent guinea pigs and immunocompromised patients, with a mean ratio of CSF to plasma concentration of 0.68 and 1.3, respectively.

In vitro susceptibilities of cerebrospinal fluid isolates of Cryptococcus neoformans collected during a ten‐year period against fluconazole, voriconazole and posaconazole (SCH56592)

Cryptococcus neoformans cerebrospinal fluid isolates showed no significant increase in susceptibility to fluconazole, voriconazole, and posaconazole over a decade, with a potential cross-resistance developing in 1996.

A flucytosine-resistant Cryptococcus neoformans (serotype D) strain isolated in turkey from cutaneous lesions.

This Cryptococcus neoformans strain from cutaneous lesions in Turkey is resistant to 5-fluorocytosine, which may cause treatment failure in some cases.

Citations